XERIS BIOPHARMA HOLDINGS INC (XERS) Fundamental Analysis & Valuation

NASDAQ:XERS • US98422E1038

Current stock price

6.01 USD
+0.09 (+1.52%)
At close:
6.01 USD
0 (0%)
After Hours:

This XERS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. XERS Profitability Analysis

1.1 Basic Checks

  • XERS had negative earnings in the past year.
  • XERS had a positive operating cash flow in the past year.
  • XERS had negative earnings in 4 of the past 5 years.
  • In the past 5 years XERS reported 4 times negative operating cash flow.
XERS Yearly Net Income VS EBIT VS OCF VS FCFXERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • The Return On Assets of XERS (0.14%) is better than 78.65% of its industry peers.
  • Looking at the Return On Equity, with a value of 4.05%, XERS belongs to the top of the industry, outperforming 82.81% of the companies in the same industry.
  • XERS has a Return On Invested Capital of 7.18%. This is amongst the best in the industry. XERS outperforms 84.38% of its industry peers.
Industry RankSector Rank
ROA 0.14%
ROE 4.05%
ROIC 7.18%
ROA(3y)-12.04%
ROA(5y)-20.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XERS Yearly ROA, ROE, ROICXERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • XERS's Profit Margin of 0.19% is fine compared to the rest of the industry. XERS outperforms 78.65% of its industry peers.
  • Looking at the Operating Margin, with a value of 8.53%, XERS belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
  • With an excellent Gross Margin value of 85.41%, XERS belongs to the best of the industry, outperforming 88.02% of the companies in the same industry.
  • XERS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.53%
PM (TTM) 0.19%
GM 85.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.42%
GM growth 5Y9.44%
XERS Yearly Profit, Operating, Gross MarginsXERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XERS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XERS is destroying value.
  • The number of shares outstanding for XERS has been increased compared to 1 year ago.
  • The number of shares outstanding for XERS has been increased compared to 5 years ago.
  • Compared to 1 year ago, XERS has an improved debt to assets ratio.
XERS Yearly Shares OutstandingXERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
XERS Yearly Total Debt VS Total AssetsXERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • XERS has an Altman-Z score of 0.61. This is a bad value and indicates that XERS is not financially healthy and even has some risk of bankruptcy.
  • XERS has a Altman-Z score (0.61) which is in line with its industry peers.
  • XERS has a debt to FCF ratio of 7.89. This is a slightly negative value and a sign of low solvency as XERS would need 7.89 years to pay back of all of its debts.
  • The Debt to FCF ratio of XERS (7.89) is better than 79.69% of its industry peers.
  • A Debt/Equity ratio of 16.10 is on the high side and indicates that XERS has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 16.10, XERS is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 16.1
Debt/FCF 7.89
Altman-Z 0.61
ROIC/WACC0.72
WACC9.91%
XERS Yearly LT Debt VS Equity VS FCFXERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 2.19 indicates that XERS has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.19, XERS is in line with its industry, outperforming 42.71% of the companies in the same industry.
  • XERS has a Quick Ratio of 1.57. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
  • XERS has a Quick ratio of 1.57. This is in the lower half of the industry: XERS underperforms 63.02% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.57
XERS Yearly Current Assets VS Current LiabilitesXERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. XERS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 97.37% over the past year.
  • XERS shows a strong growth in Revenue. In the last year, the Revenue has grown by 43.72%.
  • Measured over the past years, XERS shows a very strong growth in Revenue. The Revenue has been growing by 70.26% on average per year.
EPS 1Y (TTM)97.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y38.35%
Revenue growth 5Y70.26%
Sales Q2Q%42.78%

3.2 Future

  • XERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 158.41% yearly.
  • Based on estimates for the next years, XERS will show a quite strong growth in Revenue. The Revenue will grow by 19.20% on average per year.
EPS Next Y1951.3%
EPS Next 2Y518.97%
EPS Next 3Y289.56%
EPS Next 5Y158.41%
Revenue Next Year33.39%
Revenue Next 2Y28%
Revenue Next 3Y23.28%
Revenue Next 5Y19.2%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XERS Yearly Revenue VS EstimatesXERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
XERS Yearly EPS VS EstimatesXERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

4

4. XERS Valuation Analysis

4.1 Price/Earnings Ratio

  • XERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 32.46, XERS can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, XERS is valued a bit cheaper than the industry average as 71.88% of the companies are valued more expensively.
  • XERS is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 32.46
XERS Price Earnings VS Forward Price EarningsXERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600

4.2 Price Multiples

  • XERS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. XERS is cheaper than 77.08% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, XERS is valued a bit cheaper than the industry average as 79.17% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 37.1
EV/EBITDA 30.92
XERS Per share dataXERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • XERS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as XERS's earnings are expected to grow with 289.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y518.97%
EPS Next 3Y289.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XERS Dividend Analysis

5.1 Amount

  • XERS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XERS Fundamentals: All Metrics, Ratios and Statistics

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (4/9/2026, 8:05:38 PM)

After market: 6.01 0 (0%)

6.01

+0.09 (+1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners61.48%
Inst Owner Change0%
Ins Owners2.74%
Ins Owner Change0.77%
Market Cap1.04B
Revenue(TTM)291.85M
Net Income(TTM)554.00K
Analysts84.62
Price Target11.37 (89.18%)
Short Float %9.78%
Short Ratio8.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-33.16%
Min EPS beat(2)-100%
Max EPS beat(2)33.69%
EPS beat(4)2
Avg EPS beat(4)-3.07%
Min EPS beat(4)-100%
Max EPS beat(4)64.35%
EPS beat(8)4
Avg EPS beat(8)1.49%
EPS beat(12)6
Avg EPS beat(12)4.83%
EPS beat(16)10
Avg EPS beat(16)7.7%
Revenue beat(2)1
Avg Revenue beat(2)0.24%
Min Revenue beat(2)-1.7%
Max Revenue beat(2)2.17%
Revenue beat(4)3
Avg Revenue beat(4)2.85%
Min Revenue beat(4)-1.7%
Max Revenue beat(4)8.61%
Revenue beat(8)6
Avg Revenue beat(8)1.8%
Revenue beat(12)9
Avg Revenue beat(12)3.53%
Revenue beat(16)11
Avg Revenue beat(16)2.25%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-158.82%
EPS NQ rev (3m)-183.33%
EPS NY rev (1m)0%
EPS NY rev (3m)1.87%
Revenue NQ rev (1m)-3.61%
Revenue NQ rev (3m)-3.07%
Revenue NY rev (1m)4.44%
Revenue NY rev (3m)4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.46
P/S 3.55
P/FCF 37.1
P/OCF 36.2
P/B 75.7
P/tB N/A
EV/EBITDA 30.92
EPS(TTM)-0.01
EYN/A
EPS(NY)0.19
Fwd EY3.08%
FCF(TTM)0.16
FCFY2.7%
OCF(TTM)0.17
OCFY2.76%
SpS1.69
BVpS0.08
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.14%
ROE 4.05%
ROCE 9.09%
ROIC 7.18%
ROICexc 12.07%
ROICexgc 37.84%
OM 8.53%
PM (TTM) 0.19%
GM 85.41%
FCFM 9.57%
ROA(3y)-12.04%
ROA(5y)-20.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.42%
GM growth 5Y9.44%
F-Score8
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 16.1
Debt/FCF 7.89
Debt/EBITDA 5.95
Cap/Depr 5.73%
Cap/Sales 0.24%
Interest Coverage 0.92
Cash Conversion 77.26%
Profit Quality 5041.52%
Current Ratio 2.19
Quick Ratio 1.57
Altman-Z 0.61
F-Score8
WACC9.91%
ROIC/WACC0.72
Cap/Depr(3y)10.42%
Cap/Depr(5y)18.7%
Cap/Sales(3y)0.68%
Cap/Sales(5y)0.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y1951.3%
EPS Next 2Y518.97%
EPS Next 3Y289.56%
EPS Next 5Y158.41%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y38.35%
Revenue growth 5Y70.26%
Sales Q2Q%42.78%
Revenue Next Year33.39%
Revenue Next 2Y28%
Revenue Next 3Y23.28%
Revenue Next 5Y19.2%
EBIT growth 1Y173.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year227.83%
EBIT Next 3Y97.87%
EBIT Next 5Y62.93%
FCF growth 1Y173.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.41%
OCF growth 3YN/A
OCF growth 5YN/A

XERIS BIOPHARMA HOLDINGS INC / XERS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for XERIS BIOPHARMA HOLDINGS INC?

ChartMill assigns a fundamental rating of 4 / 10 to XERS.


What is the valuation status of XERIS BIOPHARMA HOLDINGS INC (XERS) stock?

ChartMill assigns a valuation rating of 4 / 10 to XERIS BIOPHARMA HOLDINGS INC (XERS). This can be considered as Fairly Valued.


Can you provide the profitability details for XERIS BIOPHARMA HOLDINGS INC?

XERIS BIOPHARMA HOLDINGS INC (XERS) has a profitability rating of 5 / 10.


How financially healthy is XERIS BIOPHARMA HOLDINGS INC?

The financial health rating of XERIS BIOPHARMA HOLDINGS INC (XERS) is 3 / 10.


Can you provide the expected EPS growth for XERS stock?

The Earnings per Share (EPS) of XERIS BIOPHARMA HOLDINGS INC (XERS) is expected to grow by 1951.3% in the next year.